Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation

Liesbeth ten Klooster; George D. Nossent; Johanna M. Kwakkel-van Erp; Diana A. van Kessel; Erik J. Oudijk; Ed A. van de Graaf; Bart Luijk; Rogier A. Hoek; Bernt van den Blink; Peter Th. van Hal; Erik A. Verschuuren; Wim van der Bij; Coline H  van Moorsel; Jan C  Grutters

doi:10.1007/s00408-015-9794-7

Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation

Liesbeth ten Klooster^*, George D. Nossent, Johanna M. Kwakkel-van Erp, Diana A. van Kessel, Erik J. Oudijk, Ed A. van de Graaf, Bart Luijk, Rogier A. Hoek, Bernt van den Blink, Peter Th. van Hal, Erik A. Verschuuren, Wim van der Bij, Coline H van Moorsel, Jan C Grutters

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal fibrosing lung disease with a median survival of approximately 3 years after diagnosis. The only medical option to improve survival in IPF is lung transplantation (LTX). The purpose of this study was to evaluate trajectory data of IPF patients listed for LTX and to investigate the survival after LTX.

Methods and Results Data were retrospectively collected from September 1989 until July 2011 of all IPF patients registered for LTX in the Netherlands. Patients were included after revision of the diagnosis based on the criteria set by the ATS/ERS/JRS/ALAT. Trajectory data, clinical data at time of screening, and donor data were collected. In total, 98 IPF patients were listed for LTX. During the waiting list period, 30 % of the patients died. Mean pulmonary artery pressure, 6-min walking distance, and the use of supplemental oxygen were significant predictors of mortality on the waiting list. Fifty-two patients received LTX with a median overall survival after transplantation of 10 years.

Conclusions This study demonstrated a 10-year survival time after LTX in IPF. Furthermore, our study demonstrated a significantly better survival after bilateral LTX in IPF compared to single LTX although bilateral LTX patients were significantly younger.

Original language	English
Pages (from-to)	919-926
Number of pages	8
Journal	Lung
Volume	193
Issue number	6
DOIs	https://doi.org/10.1007/s00408-015-9794-7
Publication status	Published - Dec 2015

Keywords

Interstitial lung diseases
Usual interstitial pneumonia
Organ transplantation
Outcomes
INTERNATIONAL-SOCIETY
SINGLE
BENEFIT
RISK
PIRFENIDONE
GUIDELINES
DIAGNOSIS
SELECTION
DISEASE
HEART

Access to Document

10.1007/s00408-015-9794-7

Cite this

ten Klooster, L., Nossent, G. D., Kwakkel-van Erp, J. M., van Kessel, D. A., Oudijk, E. J., van de Graaf, E. A., Luijk, B., Hoek, R. A., van den Blink, B., van Hal, P. T., Verschuuren, E. A., van der Bij, W., van Moorsel, C. H., & Grutters, J. C. (2015). Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation. Lung, 193(6), 919-926. https://doi.org/10.1007/s00408-015-9794-7

@article{4944c8affb5440d2ab04f2de2074b54a,

title = "Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation",

abstract = "Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal fibrosing lung disease with a median survival of approximately 3 years after diagnosis. The only medical option to improve survival in IPF is lung transplantation (LTX). The purpose of this study was to evaluate trajectory data of IPF patients listed for LTX and to investigate the survival after LTX.Methods and Results Data were retrospectively collected from September 1989 until July 2011 of all IPF patients registered for LTX in the Netherlands. Patients were included after revision of the diagnosis based on the criteria set by the ATS/ERS/JRS/ALAT. Trajectory data, clinical data at time of screening, and donor data were collected. In total, 98 IPF patients were listed for LTX. During the waiting list period, 30 % of the patients died. Mean pulmonary artery pressure, 6-min walking distance, and the use of supplemental oxygen were significant predictors of mortality on the waiting list. Fifty-two patients received LTX with a median overall survival after transplantation of 10 years.Conclusions This study demonstrated a 10-year survival time after LTX in IPF. Furthermore, our study demonstrated a significantly better survival after bilateral LTX in IPF compared to single LTX although bilateral LTX patients were significantly younger.",

keywords = "Interstitial lung diseases, Usual interstitial pneumonia, Organ transplantation, Outcomes, INTERNATIONAL-SOCIETY, SINGLE, BENEFIT, RISK, PIRFENIDONE, GUIDELINES, DIAGNOSIS, SELECTION, DISEASE, HEART",

author = "{ten Klooster}, Liesbeth and Nossent, {George D.} and {Kwakkel-van Erp}, {Johanna M.} and {van Kessel}, {Diana A.} and Oudijk, {Erik J.} and {van de Graaf}, {Ed A.} and Bart Luijk and Hoek, {Rogier A.} and {van den Blink}, Bernt and {van Hal}, {Peter Th.} and Verschuuren, {Erik A.} and {van der Bij}, Wim and {van Moorsel}, {Coline H} and Grutters, {Jan C}",

year = "2015",

month = dec,

doi = "10.1007/s00408-015-9794-7",

language = "English",

volume = "193",

pages = "919--926",

journal = "Lung",

issn = "0341-2040",

publisher = "Springer New York",

number = "6",

}

ten Klooster, L, Nossent, GD, Kwakkel-van Erp, JM, van Kessel, DA, Oudijk, EJ, van de Graaf, EA, Luijk, B, Hoek, RA, van den Blink, B, van Hal, PT, Verschuuren, EA, van der Bij, W, van Moorsel, CH & Grutters, JC 2015, 'Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation', Lung, vol. 193, no. 6, pp. 919-926. https://doi.org/10.1007/s00408-015-9794-7

TY - JOUR

T1 - Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation

AU - ten Klooster, Liesbeth

AU - Nossent, George D.

AU - Kwakkel-van Erp, Johanna M.

AU - van Kessel, Diana A.

AU - Oudijk, Erik J.

AU - van de Graaf, Ed A.

AU - Luijk, Bart

AU - Hoek, Rogier A.

AU - van den Blink, Bernt

AU - van Hal, Peter Th.

AU - Verschuuren, Erik A.

AU - van der Bij, Wim

AU - van Moorsel, Coline H

AU - Grutters, Jan C

PY - 2015/12

Y1 - 2015/12

N2 - Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal fibrosing lung disease with a median survival of approximately 3 years after diagnosis. The only medical option to improve survival in IPF is lung transplantation (LTX). The purpose of this study was to evaluate trajectory data of IPF patients listed for LTX and to investigate the survival after LTX.Methods and Results Data were retrospectively collected from September 1989 until July 2011 of all IPF patients registered for LTX in the Netherlands. Patients were included after revision of the diagnosis based on the criteria set by the ATS/ERS/JRS/ALAT. Trajectory data, clinical data at time of screening, and donor data were collected. In total, 98 IPF patients were listed for LTX. During the waiting list period, 30 % of the patients died. Mean pulmonary artery pressure, 6-min walking distance, and the use of supplemental oxygen were significant predictors of mortality on the waiting list. Fifty-two patients received LTX with a median overall survival after transplantation of 10 years.Conclusions This study demonstrated a 10-year survival time after LTX in IPF. Furthermore, our study demonstrated a significantly better survival after bilateral LTX in IPF compared to single LTX although bilateral LTX patients were significantly younger.

AB - Introduction Idiopathic pulmonary fibrosis (IPF) is a progressive and lethal fibrosing lung disease with a median survival of approximately 3 years after diagnosis. The only medical option to improve survival in IPF is lung transplantation (LTX). The purpose of this study was to evaluate trajectory data of IPF patients listed for LTX and to investigate the survival after LTX.Methods and Results Data were retrospectively collected from September 1989 until July 2011 of all IPF patients registered for LTX in the Netherlands. Patients were included after revision of the diagnosis based on the criteria set by the ATS/ERS/JRS/ALAT. Trajectory data, clinical data at time of screening, and donor data were collected. In total, 98 IPF patients were listed for LTX. During the waiting list period, 30 % of the patients died. Mean pulmonary artery pressure, 6-min walking distance, and the use of supplemental oxygen were significant predictors of mortality on the waiting list. Fifty-two patients received LTX with a median overall survival after transplantation of 10 years.Conclusions This study demonstrated a 10-year survival time after LTX in IPF. Furthermore, our study demonstrated a significantly better survival after bilateral LTX in IPF compared to single LTX although bilateral LTX patients were significantly younger.

KW - Interstitial lung diseases

KW - Usual interstitial pneumonia

KW - Organ transplantation

KW - Outcomes

KW - INTERNATIONAL-SOCIETY

KW - SINGLE

KW - BENEFIT

KW - RISK

KW - PIRFENIDONE

KW - GUIDELINES

KW - DIAGNOSIS

KW - SELECTION

KW - DISEASE

KW - HEART

U2 - 10.1007/s00408-015-9794-7

DO - 10.1007/s00408-015-9794-7

M3 - Article

C2 - 26404700

SN - 0341-2040

VL - 193

SP - 919

EP - 926

JO - Lung

JF - Lung

IS - 6

ER -

Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation

Abstract

Keywords

Access to Document

Fingerprint

Cite this